Indefinite Delivery Contract SPE2DR25D9636

The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, which runs through November 2026, covers a wide range of pharmaceutical products to support the medical supply needs of military health facilities worldwide, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications.

This IDC was awarded under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) solicitation, an unrestricted and fully competitive acquisition with an estimated total value of $30.3 billion. The PPV-G GEN V program aims to establish Prime Vendor Contracts to provide worldwide pharmaceutical support to the Defense Health Agency, Department of Defense, United States Coast Guard, and other government agencies. The contract includes a 30-month base period and three 30-month option periods, with awards made on a regional basis to at least three different contractors to increase the Department of Defense's resiliency and access to vital pharmaceuticals during contingencies or natural disasters.